drugset / Trial / NCT00541489

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

NCT00541489

Phase 3 Completed 800 enrolled NicOx
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To study the efficacy and safety of Naproxcinod vs. Placebo and Naproxen in the treatment of signs and symptoms of Osteoarthritis.

Timeline

Start
2007-06
Primary completion
2008-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg
Subject naproxcinod Other / unclassified 750 mg

Indications